|
Cyclin pathway genomic alterations across 5,356 prostate cancers. |
|
Denis Leonardo Fontes Jardim |
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Roche |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD |
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Janssen |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; MSD; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Daiichi Sankyo; Foundation Medicine |
Patents, Royalties, Other Intellectual Property - My husband receives royalty distributions for licensing the TRPA1 mouse model through Harvard University and Howard Hughes Medical Institute. (I) |
Travel, Accommodations, Expenses - Daiichi Sankyo; Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Research Funding - Foundation Medicine |
|
|
Employment - Foundation Medicine; Foundation Medicine |
|
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis; Genocea Biosciences |
Consulting or Advisory Role - Azitra (I); Princeptx (I); Revolution Medicines |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |
|
|
|
Stock and Other Ownership Interests - CureMatch; IDbyDNA; Soluventis |
Consulting or Advisory Role - Actuate Therapeutics; Gaido; Loxo; NeoMed; Roche; Soluventis; XBiotech |
|
Research Funding - Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst) |